SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 14131418.
  • 2
    Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352: 14071412.
  • 3
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905914.
  • 4
    Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data fron an intergroup study. Proc Am Soc Clin Oncol. 2003; 22: 252.
  • 5
    Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003; 21: 807814.
  • 6
    Medical Economics Company. 2001 Red Book. Montvale: Medical Economics Company, 2001.
  • 7
    American Medical Association. Revised 2000 National Physician Fee Schedule Relative Value File. Chicago: American Medical Association, 2000.
  • 8
    Bloomfield DJ, Krahn MD, Neogi T, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol. 1998; 16: 22722279.
  • 9
    Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Med Care. 1996; 34: 702722.
  • 10
    Earle CC, Chapman RH, Bell CM, et al. A systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18: 33023317.
  • 11
    Iglehart JK. Medicare and drug pricing. N Engl J Med. 2003; 348: 15901597.
  • 12
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.